Earnings summaries and quarterly performance for BIOCRYST PHARMACEUTICALS.
Executive leadership at BIOCRYST PHARMACEUTICALS.
Board of directors at BIOCRYST PHARMACEUTICALS.
Research analysts who have asked questions during BIOCRYST PHARMACEUTICALS earnings calls.
Brian Abrahams
RBC Capital Markets
6 questions for BCRX
Also covers: ACAD, ATAI, BIIB +19 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for BCRX
Also covers: ALKS, ALNY, AMRN +23 more
LC
Laura Chico
Wedbush Securities
4 questions for BCRX
Also covers: APLS, ARDX, BHVN +11 more
SB
Serge Belanger
Needham & Company
4 questions for BCRX
Also covers: AMPH, ARQT, CLSD +13 more
SK
Stacy Ku
TD Cowen
4 questions for BCRX
Also covers: AUPH, KALV, RVNC +3 more
HW
Huidong Wang
Barclays
3 questions for BCRX
Also covers: ALNY, BEAM, BLUE +15 more
MR
Maurice Raycroft
Jefferies Financial Group
3 questions for BCRX
Also covers: ABEO, AFMD, ALNY +14 more
TA
Tazeen Ahmad
Bank of America
3 questions for BCRX
Also covers: ACAD, ALNY, APLS +22 more
Amy
UBS
2 questions for BCRX
Also covers: AVB
C
Catherine
Citizens
2 questions for BCRX
Also covers: KALV, OCUL
J
John
Raymond James
2 questions for BCRX
Also covers: BOX, GTM, SONO +1 more
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
2 questions for BCRX
Also covers: ALT, CLSD, DBVT +6 more
Liisa Bayko
Evercore ISI
2 questions for BCRX
Also covers: ALT, INSM, IPHA +7 more
MV
Mikaela Vanik
Stifel Financial Corp.
2 questions for BCRX
V
Vish
TD Cowen
2 questions for BCRX
Gena Wang
Barclays
1 question for BCRX
Also covers: ALNY, BLUE, BMRN +13 more
JW
Jon Wolleben
Citizen JMP
1 question for BCRX
Also covers: CLSD, CRNX, MDGL +4 more
MR
Maury Raycroft
Jefferies
1 question for BCRX
Also covers: ABEO, ALNY, ARWR +14 more
Seema Sheoran
Evercore ISI
1 question for BCRX
SS
Steven Seedhouse
Raymond James
1 question for BCRX
Also covers: APLS, EDIT, GLMD +2 more
Steve Seedhouse
Cantor Fitzgerald
1 question for BCRX
Also covers: BOLD, HROW, VKTX +1 more
Recent press releases and 8-K filings for BCRX.
BioCryst Pharmaceuticals Announces Q4 and Full Year 2025 Results and FY 2026 Guidance
BCRX
Earnings
Guidance Update
Product Launch
- BioCryst Pharmaceuticals reported FY 2025 GAAP ORLADEYO revenue of $602 million and Non-GAAP ORLADEYO revenue of $563 million, compared to $438 million (GAAP) and $395 million (Non-GAAP) in FY 2024.
- The company achieved FY 2025 GAAP operating profit of $341 million and Non-GAAP operating profit of $214 million, a significant increase from FY 2024 GAAP operating loss of $(3) million and Non-GAAP operating profit of $72 million.
- For FY 2026, BioCryst Pharmaceuticals provided guidance for ORLADEYO revenue between $625 million and $645 million and total revenue between $635 million and $660 million.
- ORLADEYO, which had its pediatric formulation approved on December 12, 2025, served over 1,600 patients in the US market by year-end 2025.
- As of December 31, 2025, pro forma cash and investments totaled $279 million, with a $400 million senior credit facility drawn on January 23, 2026.
2 days ago
BioCryst Pharmaceuticals Reports Strong 2025 Results, Provides 2026 Guidance, and Advances Pipeline
BCRX
Earnings
Guidance Update
M&A
- BioCryst Pharmaceuticals reported full-year 2025 ORLADEYO revenue of $601.8 million, an increase of 38% year-over-year, or 43% excluding the European business sale, and achieved a non-GAAP operating profit of $214 million, up 198% year-over-year.
- The company ended 2025 with a strong liquidity position of $337.5 million in cash and investments and secured a $400 million financing facility with Blackstone Life Sciences.
- For 2026, BioCryst expects ORLADEYO revenues between $625 million and $645 million, representing approximately 13% growth over 2025 adjusted revenues, and non-GAAP operating expenses between $450 million and $470 million.
- Strategic initiatives include the acquisition of Astria Therapeutics, the launch of ORLADEYO Pellets for pediatric patients, and the advancement of navenibart, with regulatory submission targeted by end of 2027 and approval by late 2028.
2 days ago
BioCryst Pharmaceuticals Reports Strong 2025 Results, Acquires Astria Therapeutics, and Launches ORLADEYO Pellets
BCRX
Earnings
M&A
Product Launch
- BioCryst Pharmaceuticals reported full-year 2025 ORLADEYO revenue of $601.8 million, representing a 38% increase year-over-year, or 43% when excluding the European business sale.
- The company achieved record profitability in 2025, with non-GAAP operating profit reaching $214 million, a 198% increase year-over-year, and ended the year with $337.5 million in cash and investments.
- BioCryst expanded its HAE portfolio with the acquisition of Astria Therapeutics in January 2026, concurrent with securing $400 million in financing facilities.
- The ORLADEYO Pellets for children aged 2 to under 12 received FDA approval in December 2025 and are being launched, with full-year 2026 ORLADEYO revenues projected to be between $625 million and $645 million.
- The pivotal phase 3 trial for navenibart is progressing well, with enrollment expected to complete around mid-2026, following strong phase 2 results showing 90-92% reductions in mean attack rates.
2 days ago
BioCryst Reports Strong 2025 Financial Results and Expands HAE Portfolio
BCRX
Earnings
Product Launch
M&A
- BioCryst closed 2025 with strong momentum, delivering full-year ORLADEYO revenue of $601.8 million, which was up 38% for the year, or 43% when excluding the Europe business sold in October.
- The company achieved record profitability in 2025, with non-GAAP operating profit increasing 198% year-on-year to $214 million, and ended the year with a liquidity position of $337.5 million in cash and investments.
- BioCryst expanded its HAE portfolio with the acquisition of Astria Therapeutics in January and the launch of ORLADEYO Pellets for children aged 2 to under 12.
- For 2026, the company anticipates ORLADEYO revenue to be between $625 million and $645 million, with Q1 revenue expected to be slightly down compared to Q4 2025 due to the reauthorization season.
2 days ago
BioCryst Reports Record Full Year 2025 Financial Results and Strategic Business Updates
BCRX
Earnings
Guidance Update
M&A
- BioCryst Pharmaceuticals, Inc. reported full year 2025 ORLADEYO net revenue of $601.8 million, marking a 38% year-over-year increase, and achieved full-year profitability for the first time in its history.
- For the full year 2025, the company reported total revenues of $874.8 million, a GAAP operating profit of $341.0 million, and net income of $263.861 million.
- Strategic business developments included the sale of its European ORLADEYO business in October 2025 and the acquisition of Astria Therapeutics in January 2026, expanding its HAE portfolio.
- The FDA approved ORLADEYO oral pellets for HAE patients aged 2 to <12 years in December 2025, and the company maintained its full year 2026 ORLADEYO revenue guidance between $625 million and $645 million.
2 days ago
BioCryst Completes Acquisition of Astria Therapeutics
BCRX
M&A
Debt Issuance
Board Change
- BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. on January 23, 2026, strengthening its leadership in hereditary angioedema (HAE).
- The acquisition adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development for HAE, and Astria's early-stage program for atopic dermatitis, STAR0310, to BioCryst's portfolio.
- The transaction was valued at approximately $700 million, net of Astria's cash, and was financed by cash on hand, approximately $396.6 million from a Blackstone financing facility, and the issuance of approximately 37.3 million shares of BioCryst common stock.
- Jill C. Milne, Ph.D., Astria's former Co-Founder and CEO, joined BioCryst's Board of Directors, and John Ruesch, Astria's former Senior Vice President, joined BioCryst as Chief Technical Operations Officer.
Jan 23, 2026, 9:30 PM
BioCryst Completes Acquisition of Astria Therapeutics
BCRX
M&A
New Projects/Investments
Board Change
- BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. on January 23, 2026, strengthening its position as a leader in hereditary angioedema (HAE).
- The acquisition, with an implied transaction value of approximately $700 million net of Astria’s cash, adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development for HAE, to BioCryst's portfolio.
- BioCryst financed the cash portion using cash on hand and approximately $396.6 million (net of expenses) from a Blackstone financing facility, and issued approximately 37.3 million shares of its common stock to Astria’s equity holders.
- BioCryst also obtained Astria’s early-stage program for atopic dermatitis, STAR0310, for which the company plans to pursue strategic alternatives.
- Jill C. Milne, Ph.D., former Co-Founder and CEO of Astria Therapeutics, has joined the BioCryst Board of Directors.
Jan 23, 2026, 2:00 PM
BioCryst Announces Preliminary Full Year 2025 ORLADEYO Net Revenue and 2026 Guidance
BCRX
Earnings
Guidance Update
M&A
- BioCryst Pharmaceuticals reported preliminary, unaudited ORLADEYO net revenue of $601 million for full year 2025, exceeding its prior guidance range.
- Preliminary, unaudited ORLADEYO net revenue for the fourth quarter of 2025 was $151 million.
- For full year 2026, the company expects global net ORLADEYO revenue to be between $625 million and $645 million, and total revenue between $635 million and $660 million.
- BioCryst anticipates continued non-GAAP profitability in 2026 and reported preliminary cash, cash equivalents, restricted cash & investments of $338 million as of December 31, 2025.
- Full year 2026 non-GAAP operating expenses are projected to be between $380 million and $390 million, or between $450 million and $470 million including the expected Astria acquisition.
Jan 12, 2026, 9:28 PM
BioCryst Reports Strong 2025 Results, Provides 2026 Guidance, and Advances Strategic Pipeline
BCRX
M&A
Guidance Update
New Projects/Investments
- BioCryst reported preliminary 2025 ORLADEYO revenue of $601 million, exceeding its latest guidance, and achieved profitability for the first time in company history, ending the year with nearly $340 million in cash.
- The company provided 2026 guidance, anticipating ORLADEYO revenue of $625-$645 million and total revenue of $635-$660 million, with non-GAAP base operating expenses projected at $380-$390 million.
- BioCryst sold its European business for $250 million in cash and expects to close the acquisition of Astria Therapeutics, adding the late-stage HAE asset Novanavart, which is projected to contribute to double-digit revenue growth into the 2030s alongside ORLADEYO.
- ORLADEYO received pediatric approval for ages two and up and is on track to reach $1 billion in peak sales by 2029. The company is also advancing BCX 17725 for Netherton Syndrome, with proof of concept data expected by the end of 2026.
Jan 12, 2026, 6:30 PM
BioCryst Pharmaceuticals Reports Strong 2025 Results, Provides 2026 Guidance, and Details Strategic Acquisitions
BCRX
M&A
Guidance Update
New Projects/Investments
- BioCryst Pharmaceuticals reported $601 million in ORLADEYO revenue for 2025, exceeding its latest guidance, and anticipates $625 million-$645 million in ORLADEYO revenue and $635 million-$660 million in total revenue for 2026. The company achieved profitability for the first time in 2025 and expects to remain profitable going forward.
- The company sold its European business for $250 million in cash upfront and is in the process of acquiring Astria Therapeutics for $700 million in total enterprise value, with the deal expected to close in the next couple of weeks.
- ORLADEYO saw its most new patient prescriptions in the U.S. in 2025 since its launch year and received approval for pediatric use down to age two. The company projects ORLADEYO to reach $1 billion in peak sales by 2029.
- The acquisition of Astria Therapeutics adds navenibart, a late-stage rare disease HAE asset, to the pipeline, which is expected to contribute to double-digit revenue growth into the 2030s. BioCryst is also advancing BCX17725 for Netherton Syndrome, with proof-of-concept data expected by the end of 2026.
Jan 12, 2026, 6:30 PM
Quarterly earnings call transcripts for BIOCRYST PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more